|
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD.
The study wil be conducted by partners Shionogi & Co Ltd, and is designed to evaluate the safety and efficacy of the product in children aged six to 17.
Results of the study are expected in the second half of 2023.
Current stock price: 195.40 pence
12-month change: down 40%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
